Drug Profile
JVRS 100
Alternative Names: JVRS-100Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Juvaris BioTherapeutics
- Developer Penn State Milton S. Hershey Medical Center
- Class Adjuvants; Antineoplastics; DNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Leukaemia